Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction

Swedish Orphan Biovitrum AB

www.sobi.com

Latest From Swedish Orphan Biovitrum AB

Bookmark
  • Analysis

REMS Abuse Website: Has It Changed The Behavior Of Innovators?

By Michael Cipriano
Updated numbers from the US FDA's REMS abuse website show that Celgene has received two additional safety determination letters, raising question's about whether the public list has changed the practices of brand companies hindering generic company access to samples.
Generic Drugs Risk Management
Bookmark
  • News

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019

By Michael Cipriano
The latest drug development news and highlights from our US FDA Performance Tracker.
US FDA Performance Tracker Drug Review
Bookmark
  • Interviews

Profitable Pharming Expands Ruconest Potential And Resurrects Pompe Pipeline

By Jo Shorthouse

Dutch rare disease company Pharming talked to Scrip about turning a profit for the first time in the company’s history, finally restocking the pipeline in potentially blockbuster indications, and turning its attention back to Pompe disease after 20 years in the cold.

Rare Diseases Companies
Bookmark
  • Analysis

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

By Joseph Haas, Jo Shorthouse, John Davis and Eleanor Malone

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Sobi
  • Biovitrum AB
  • Swedish Orphan Biovitrum
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Swedish Orphan Biovitrum AB
  • Senior Management
  • Guido Oelkers, PhD, CEO
    Henrik Stenqvist, CFO
    Milan Zdravkovic, MD, PhD, Head, R&D & CMO
  • Contact Info
  • Swedish Orphan Biovitrum AB
    Phone: (46) 8 697 20 00
    Tomtebodavägen 23A
    Stockholm, SE-112 76
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By